PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
465.48
P/E exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.85. Michael Burry would check for market euphoria. Scrutinize growth expectations.
790.12
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.70. Jim Chanos would check for potential multiple compression risks.
67.44
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.05. Jim Chanos would check for potential asset write-down risks.
-7493.15
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is 0.00. Seth Klarman would investigate cash flow improvement potential.
7955.83
P/OCF of 7955.83 versus zero operating cash flow in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify operational quality.
67.44
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.05. Jim Chanos would check for valuation bubble risks.
0.05%
Earnings yield near Drug Manufacturers - Specialty & Generic median of 0.06%. Charlie Munger would verify if industry-standard yields make sense.
-0.01%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is 0.00%. Seth Klarman would investigate cash flow improvement potential.